Qualtix Stock Brief
Eli Lilly and Company (LLY) stock analysis: business quality, valuation, and entry timing
Eli Lilly is a pharmaceutical company with a portfolio across diabetes, obesity, oncology, immunology, and neuroscience. Fast growth from new medicines can push valuation far ahead of today's earnings, which is why the model keeps quality and price separate. Public Qualtix model snapshot from 2026-10-26 for LLY: business quality 88/100, a strong model reading and valuation Cheap. Today's verdict and Entry Timing are shown after a free sign-in.
Qualtix evaluates LLY with a rules-based model that separates business quality, valuation, entry timing, red flags, and data confidence. The model scores first; AI explanations and the full Clean Brief help explain the result afterward.
Coverage note: Qualtix can analyze supported US stocks when SEC/FMP filing data is available. The 1,000+ stock universe refers to the daily screener used for discovery, not the full analysis limit.
LLY public evidence metrics from the latest validated Qualtix snapshot
| Metric | Value | Why it matters | Source |
|---|---|---|---|
| Revenue growth | 39.2% | 3-year revenue CAGR | FMP, computed |
| FCF margin | 25.2% | Free cash flow divided by revenue | FMP, computed |
| Operating margin | 49.7% | Profitability margin | FMP, computed |
| Gross margin | 83.4% | Revenue retained after direct costs | FMP, computed |
| Return on capital (pre-tax) | 44.6% | Operating profit before tax, divided by equity plus debt | FMP, computed |
| ROE | 78.8% | Return on equity | FMP, computed |
| Cash and debt | Cash and investments $8.9B / Debt $54.9B | Balance-sheet context | FMP, reported |
| TTM P/E | 45.1x | Price to trailing earnings | FMP, computed |
Qualtix view
- Business quality: 88/100, a strong model reading.
- Valuation is currently labeled Cheap, so price is a supporting part of the model view.
Today's verdict
- Today's model verdict and Entry Timing for LLY update every market day and are shown after a free sign-in.
Data and snapshot dates
- Model snapshot date: 2026-10-26.
- Financial data through: 2026-06-30.
- Scored by the current Qualtix model.
- Data-confidence status: high.
What supports the current view
- Business quality is a major strength in the public model snapshot (88/100).
- Valuation is labeled Cheap by the current model view.
- Beta of 0.45 suggests lower market sensitivity than higher-beta alternatives.
What weakens the current view
- A public snapshot is a research starting point, not a prediction or recommendation.
What changed
- Business Quality was unchanged from the previous snapshot.
What to research next
- Verify whether Eli Lilly and Company's moat, margins, growth, and capital efficiency still justify a 88/100 Business Quality score.
- Check whether the Cheap valuation label reflects a real mismatch or a business concern that deserves more research.
- Compare LLY with ABBV and MRK to see whether the model edge is company-specific or sector-wide.
Follow Qualtix on X, TikTok, LinkedIn, YouTube.
Qualtix is for research and education only. It is not financial advice.